ATAI Raises $125m Series C To Expand The Boundaries In Mental Health

Portfolio Includes Psychedelic And Non-Psychedelic Drugs

 
• By Alaric DeArment
  
Business, Technology, Internet and network concept. Young businessman working on a virtual screen of the future and sees the inscription: venture capital
ATAI Life Sciences raised $125m to fund preclinical and clinical mental health programs. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D